These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 11113845

  • 1. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.
    Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR.
    J Pediatr; 2000 Dec; 137(6):865-70. PubMed ID: 11113845
    [Abstract] [Full Text] [Related]

  • 2. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [Abstract] [Full Text] [Related]

  • 3. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R, Dooley L, Bruden D, Raelson S, Butler JC.
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [Abstract] [Full Text] [Related]

  • 4. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children.
    Madhi SA, Kuwanda L, Cutland C, Klugman KP.
    J Clin Virol; 2006 Jul; 36(3):215-21. PubMed ID: 16678480
    [Abstract] [Full Text] [Related]

  • 5. School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants.
    Greenough A, Alexander J, Boit P, Boorman J, Burgess S, Burke A, Chetcuti PA, Cliff I, Lenney W, Lytle T, Morgan C, Raiman C, Shaw NJ, Sylvester KP, Turner J.
    Thorax; 2009 Jun; 64(6):490-5. PubMed ID: 19213770
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA, Carbonell-Estrany X.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [Abstract] [Full Text] [Related]

  • 8. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T, Rozé JC, Fauroux B, French Pediatricians' Group of Sunagis Patients' Name-Based Programs.
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [Abstract] [Full Text] [Related]

  • 9. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 10. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O.
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
    Stewart DL, Romero JR, Buysman EK, Fernandes AW, Mahadevia PJ.
    Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
    [Abstract] [Full Text] [Related]

  • 14. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, Palivizumab Outcomes Registry Group.
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC.
    N Engl J Med; 1993 Nov 18; 329(21):1524-30. PubMed ID: 8413475
    [Abstract] [Full Text] [Related]

  • 20. [Respiratory syncytial virus prophylaxis among preterm infants--four seasons' experience].
    Klimek M, Kwinta P, Kruczek P, Pietrzyk JJ.
    Przegl Lek; 2009 Nov 18; 66(1-2):34-8. PubMed ID: 19485253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.